| Document and Entity Information | Mar. 09, 2023 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001894562 |
| Document Type | 8-K/A |
| Document Period End Date | Mar. 09, 2023 |
| Entity Registrant Name | Prime Medicine, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-41536 |
| Entity Tax Identification Number | 84-3097762 |
| Entity Address, Address Line One | 21 Erie Street |
| Entity Address, City or Town | Cambridge |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02139 |
| City Area Code | (617) |
| Local Phone Number | 564-0013 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.00001 par value per share |
| Trading Symbol | PRME |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | This Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed by Prime Medicine, Inc. (the “Company”) with the U.S. Securities and Exchange Commission on March 9, 2023 (the “Original Form 8-K”). The Original Form 8-K furnished with the Securities and Exchange Commission an earnings release containing the Company’s financial results for the fourth quarter and year ended December 31, 2022. The sole purpose of this Amendment is to furnish a revised earnings release that corrects inadvertent errors in the earlier release that misstated the year-ended column headings in the Condensed Consolidated Balance Sheet Data (unaudited) table and the total liabilities for the year ended December 31, 2021. The updated version of the earnings release is furnished as Exhibit 99.1 hereto. No other modifications have been made to the Original Form 8-K. |
